Aims and Methods: Prediction algorithms suggest factors determining short- and long-term growth response to growth hormone (GH) in Turner’s syndrome (TS). A total of 133 patients (group A; 53% with karyotype 45,X) completed 1 year of treatment and 77 patients (group B) reached adult height (AH) after >4 years on GH treatment. The patients were analysed for factors determining the outcomes, and in addition, the validity of published algorithms was tested. Results: In group A [values are given as medians (10th–90th percentiles)], starting age was 9.4 (4.8–14) years, height was –3.2 (–4.4 to –1.9) SDS (Prader references), and GH dose was 38 (23–48) µg/kg/day. Observed height velocity was 7.7 (5.2–9.8) cm/years and was equal to the predicted height velocity. In group B, projected adult height (PAH) was 147.4 (139.5–154.8) cm. Total gain in height over PAH of 6.1 (2.0–12.6) cm was negatively correlated with height at start, but positively correlated with GH duration, first year Δheight SDS, or index of responsiveness. Observed AH was 153.5 (146.6–160.1) cm and predicted AH was 155.0 (147.4–161.0) cm, which is statistically not different. On GH <5% IGF-I levels were >2 SDS. Conclusions: The published prediction algorithms were found to be valid. If normal AH is to be reached at the lowest costs and risks, probably only TS children with a good growth potential and a high responsiveness to GH can be treated successfully with GH doses of <50 µg/kg/day.

1.
Ranke MB, Grauer ML: Adult height in Turner syndrome: results of a multinational survey 1993. Horm Res 1994;42:90–94.
2.
Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J, Lippe BM, Mahoney CP, Moore WV, Saenger P, Johanson AJ: Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr 1998;132:319–324.
3.
van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwé CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL: Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88:1119–1125.
4.
Stephure DK; Canadian Growth Hormone Advisory Committee: Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90:3360–3366.
5.
Carel JC, Butler G: Safety of recombinant human growth hormone. Endocr Dev 2010;18:40–54.
6.
Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA; KIGS International Board: Kabi International Growth Study. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J Clin Endocrinol Metab 2000;85:4212–4218.
7.
Ranke MB, Lindberg A, Ferrández Longás A, Darendeliler F, Albertsson-Wikland K, Dunger D, Cutfield WS, Tauber M, Wilton P, Wollmann HA, Reiter EO; KIGS International Board: Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatr Res 2007;61:105–110.
8.
Ranke MB, Pflüger H, Rosendahl W, Stubbe P, Enders H, Bierich JR, Majewski F: Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr 1983;141:81–88.
9.
Schweizer R, Ranke MB, Binder G, Herdach F, Zapadlo M, Grauer ML, Schwarze CP, Wollmann HA: Experience with growth hormone therapy in Turner syndrome in a single centre: low total height gain, no further gains after puberty onset and unchanged body proportions. Horm Res 2000;53:228–238.
10.
Bondy CA; for the Turner Syndrome Consensus Study Group: Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group J Clin Endocrinol Metab 2007;92:10–25.
11.
Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P: An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977–1981). Acta Paediatr Scand 1991;80:756–762.
12.
Prader A, Largo RH, Molinari L, Issler C: Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta 1989;(suppl 52):1–125.
13.
Lyon AJ, Preece MA, Grant DB: Growth curve for girls with Turner syndrome. Arch Dis Child 1985;60:932–935.
14.
Cole TJ: Some questions about how growth standards are used. Horm Res 1996;45(suppl 2):18–23.
15.
Greulich WW, Pyle SI: Radiographic atlas of skeletal development of the hand and wrist. Stanford California. Stanford University Press, 1959.
16.
Hauffa BP, Lehmann N, Bettendorf M, Mehls O, Dörr HG, Stahnke N, Steinkamp H, Said E, Ranke MB; German KIGS Board/Medical Outcome Study Group: Central laboratory reassessment of IGF-I, IGF-binding protein-3, and GH serum concentrations measured at local treatment centers in growth-impaired children: implications for the agreement between outpatient screening and the results of somatotropic axis functional testing. Eur J Endocrinol 2007;157:597–603.
17.
Blum WF, Schweizer R: Insulin-like growth factors and their binding proteins; in Diagnostics of Endocrine Function in Children and Adolescents, 3rd ed., Ranke MB (ed): 2003, Karger, Basel, pp 166–199.
18.
Reiter EO, Blethen SL, Baptista J, Price L: Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner´s syndrome. J Clin Endocrinol Metab 2001;86:1936–1941.
19.
Ranke MB, Saenger P: Turner’s syndrome. Lancet 2001;358:309–314.
20.
Baxter L, Bryant J, Cave CB, Milne R: Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev 2007;CD003887.
21.
Hofman P, Cutfield WS, Robinson EM, Clavano A, Ambler GR, Cowell C: Factors predictive of response to growth hormone therapy in Turner’s syndrome. J Pediatr Endocrinol Metab 1997;10:27–33.
22.
Plotnick L, Attie KM, Blethen SL, Sy JP: Growth hormone treatment of girls with Turner syndrome: the National Cooperative Growth Study experience. Pediatrics 1998;102:479–481.
23.
Soriano-Guillen L, Coste J, Ecosse E, Léger J, Tauber M, Cabrol S, Nicolino M, Brauner R, Chaussain JL, Carel JC: Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab 2005;90:5197–5204.
24.
van Teunenbroek A, de Muinck Keizer- Schrama SM, Stijnen T, Jansen M, Otten BJ, Delemarre-van de Waal HA, Vulsma T, Wit JM, Rouwé CW, Reeser HM, Gosen JJ, Rongen-Westerlaken C, Drop SL: Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone. J Clin Endocrinol Metab 1996;81:4013–4021.
25.
Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, Gunther DF, Liu C, Geffner ME, Thrailkill K, Huseman C, Zagar AJ, Quigley CA: Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:3406–3416.
26.
Linglart A, Cabrol S, Berlier P, Stuckens C, Wagner K, De Kerdanet M, Limoni C, Carel JC, Chaussain JL: Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome. Eur J Endocrinol 2011, E-pub ahead of print.
27.
Hughes IP, Choong CS, Harris M, Ambler GR, Cutfield WS, Hofman PL, Cowell CT, Werther G, Cotterill A, Davies PS; Australasian Paediatric Endocrine Group (APEG): Growth hormone treatment for Turner syndrome in Australia reveals that younger age and increased dose interact to improve response. Clin Endocrinol (Oxf) 2011;74:473–480.
28.
Hochberg Z, Zadik Z: Final height in young women with Turner syndrome after GH therapy: an open controlled study. Eur J Endocrinol 1999;141:218–224.
29.
Ranke MB, Partsch CJ, Lindberg A, Dorr HG, Bettendorf M, Hauffa BP, Schwarz HP, Mehls O, Sander S, Stahnke N, Steinkamp H, Said E, Sippell W: Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: results of the German IGLU Follow-up Study 2001.Eur J Endocrinol 2002;147:625–633.
30.
Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA: Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997;16:54–63.
31.
Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton PE: Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol (Oxf) 2000;53:329–336.
32.
Cutfield WS, Lundgren F: Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, Turner syndrome and born small for gestational age. HormRes 2009;71(suppl 1):39–45.
33.
Ranke MB: Insulin-like growth factor 1 levels in patients within the KIGS database; in Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics – 20 years of KIGS. Basel: Karger, 2007, pp 83–92.
34.
Park P, Cohen P: The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res 2004;62(suppl 1):59–65.
35.
Das U, Whatmore AJ, Khosravi J, Wales JK, Butler G, Kibirige MS, Diamandi A, Jones J, Patel L, Hall CM, Price DA, Clayton PE: IGF-I and IGF-binding protein-3 measurements on filter paper blood spots in children and adolescents on GH treatment: use in monitoring and as markers of growth performance. Eur J Endocrinol 2003;149:179–185.
36.
Samani AA, Yakar S, LeRoith D, Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20–47.
37.
Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M: Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346–1353.
38.
Ranke MB, Lindberg A; on behalf of the KIGS International Board: Observed and predicted total pubertal growth (TPG) during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency (GHD), Turner syndrome (TS), short stature born small for gestational age (SGA) and idiopathic short stature (ISS). KIGS analysis and review. Horm Res Paed 2011;75:423–432.
39.
Ranke MB, Lindberg A; KIGS International Board: Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010;95:1229–1237.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.